Company intelligence / Profile preview

VISUMAB

Ownership: Private
Development stage: Other

Overview

VisuMax is an early-stage biotechnology company focused on developing innovative antibody-based therapies for ophthalmic diseases. The company's primary focus is on addressing unmet needs in retinal disorders, such as wet age-related macular degeneration and diabetic macular edema, through the engineering of high-affinity monoclonal antibodies. By leveraging advanced protein engineering techniques, VisuMax aims to create next-generation biologics with improved durability and efficacy compared to current standards of care. The company is currently progressing its lead candidates through pre-clinical validation and optimization.

Therapeutic areas: Ophthalmology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Beyond the preview

Go deeper on VISUMAB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VISUMAB.

Explore the full profile